We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 416.9992 0.2113% AAPL 231.83 0.0216% NVDA 138.895 2.3394% GOOGL 163.53 -0.9869% GOOG 165.1 -0.9836% AMZN 187.78 0.4762% META 578.1245 0.2314% AVGO 183.5976 3.8331% TSLA 220.4371 -0.4034% TSM 207.9713 10.9299% LLY 917.515 -0.5652% V 289.845 0.8086% JPM 224.705 0.4762% UNH 568.2 -0.5496% NVO 118.43 0.3389% WMT 80.845 -0.4617% LVMUY 131.3 0.6439% XOM 120.36 -0.2486% LVMHF 659.0 1.0345% MA 513.11 -0.1867%

Predictive Oncology Inc

Healthcare US POAI

0.5853USD
-0.0099(1.66%)

Last update at 2024-10-17T18:57:00Z

Day Range

0.580.60
LowHigh

52 Week Range

1.127.12
LowHigh

Fundamentals

  • Previous Close 0.60
  • Market Cap8.55M
  • Volume50335
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.18201M
  • Revenue TTM1.78M
  • Revenue Per Share TTM0.44
  • Gross Profit TTM 1.00M
  • Diluted EPS TTM-4.9

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -25.73763M -20.31883M -25.88440M -19.39077M -10.08648M
Minority interest - - - - -
Net income -36.20755M -19.65717M -37.70167M -27.55613M -10.08648M
Selling general administrative 11.11M 10.93M 10.35M 9.78M 4.63M
Selling and marketing expenses 1.36M 0.77M 0.58M 1.91M 2.37M
Gross profit 1.00M 0.93M 0.81M 0.88M 1.00M
Reconciled depreciation 1.31M 1.34M 1.02M 0.70M 0.15M
Ebit -15.26772M -13.47156M -0.66627M -13.77449M -7.86138M
Ebitda -3.30435M -6.67940M 0.36M -4.90424M -7.71375M
Depreciation and amortization 11.96M 6.79M 1.02M 8.87M 0.15M
Non operating income net other - - -1.81436M - -
Operating income -15.26772M -13.47156M -0.66627M -13.77449M -7.86138M
Other operating expenses 16.77M 14.89M 13.74M 15.19M 9.27M
Interest expense 10.65M 12.30M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M -0.66166M - - -
Interest income - - - 5.72M 2.29M
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - 12.88M - -
Other items - - - - -
Income tax expense 10.47M -0.66166M 11.82M 8.17M -2.22510M
Total revenue 1.51M 1.42M 1.25M 1.41M 1.41M
Total operating expenses 16.27M 14.41M 13.29M 14.65M 8.86M
Cost of revenue 0.51M 0.49M 0.45M 0.53M 0.42M
Total other income expense net -10.46992M -6.84727M -25.21813M -5.61627M -2.22510M
Discontinued operations - - - - -
Net income from continuing ops -25.73763M -19.65717M -25.88440M -19.39077M -10.08648M
Net income applicable to common shares -25.73763M -19.65717M -26.43868M -19.68070M -10.08648M
Preferred stock and other adjustments - - 0.55M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 14.42M 25.73M 43.77M 13.06M 22.38M
Intangible assets 0.25M 0.25M 3.96M 3.40M 3.65M
Earning assets - - - - -
Other current assets 0.52M 0.53M 0.51M 0.29M 0.16M
Total liab 6.15M 3.97M 3.51M 10.42M 11.14M
Total stockholder equity 8.27M 21.77M 40.27M 2.64M 11.23M
Deferred long term liab - - - - -
Other current liab 1.63M 2.24M 1.39M 2.88M 2.42M
Common stock 0.04M 0.79M 0.66M 0.20M 0.04M
Capital stock 0.04M 0.79M 0.66M 0.20M 0.08M
Retained earnings -167.76188M -153.77792M -128.04028M -108.38311M -82.49871M
Other liab - - 0.03M 0.24M -
Good will - 0.00000M 6.86M 2.81M 15.69M
Other assets - 0.08M 0.17M 1.51M -
Cash 8.73M 22.07M 28.20M 0.68M 0.15M
Cash and equivalents - - - - -
Total current liabilities 3.95M 3.88M 3.24M 9.34M 10.87M
Current deferred revenue 0.31M 0.60M 0.19M 0.05M 0.04M
Net debt -5.87185M -21.89120M -27.32329M 5.20M 5.37M
Short term debt 0.67M 0.09M 0.64M 5.03M 5.26M
Short long term debt 0.15M - - 4.43M 4.80M
Short long term debt total 2.86M 0.18M 0.88M 5.87M 5.53M
Other stockholder equity 175.99M 174.76M 167.65M 110.83M 93.65M
Property plant equipment - 2.05M 3.33M 5.22M 2.24M
Total current assets 10.08M 23.36M 29.46M 1.51M 0.80M
Long term investments - - - - -
Net tangible assets - 21.51M 29.44M -3.57000M -8.14418M
Short term investments - - - - -
Net receivables 0.33M 0.33M 0.35M 0.26M 0.30M
Long term debt - - - - -
Inventory 0.49M 0.43M 0.39M 0.29M 0.19M
Accounts payable 1.34M 0.94M 1.02M 1.37M 3.16M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00079M - - - -0.77157M
Additional paid in capital - - - - -
Common stock total equity - - - 0.20M 0.04M
Preferred stock total equity - - - 0.00079M -
Retained earnings total equity - - - -108.38311M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.13M 0.08M 0.17M 0.12M 21.58M
Deferred long term asset charges - - - - -
Non current assets total 4.34M 2.37M 14.31M 11.55M 21.58M
Capital lease obligations 2.71M 0.18M 0.88M 1.44M 0.73M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.47570M -10.60754M -0.16746M -0.59909M -1.11065M
Change to liabilities -0.03650M -0.29575M -1.64351M 0.38M 0.32M
Total cashflows from investing activities -0.47570M -10.60754M -0.16746M -0.59909M -1.11065M
Net borrowings - -4.16274M 1.29M 1.54M 2.19M
Total cash from financing activities 6.72M 50.34M 12.95M 9.32M 5.79M
Change to operating activities 0.92M -0.77972M 0.46M 1.26M 0.63M
Net income -25.73763M -19.65717M -25.88440M -19.39077M -10.08648M
Change in cash -6.13109M 27.52M 0.53M -0.01132M -0.60404M
Begin period cash flow 28.20M 0.68M 0.15M 0.16M 0.77M
End period cash flow 22.07M 28.20M 0.68M 0.15M 0.16M
Total cash from operating activities -12.37080M -12.20893M -12.25773M -8.73245M -5.28796M
Issuance of capital stock 6.74M 51.20M 9.95M 7.98M 2.96M
Depreciation 1.31M 1.34M 1.02M 0.70M 0.15M
Other cashflows from investing activities - - 0.13M -0.82058M -1.12362M
Dividends paid - 4.51M 2962.77M - -
Change to inventory -0.04281M -0.09815M -0.09471M 0.09M 0.02M
Change to account receivables 0.02M -0.02077M 0.07M 0.14M -0.09510M
Sale purchase of stock -0.02765M -0.01153M 2962.77M 7.99M 3.61M
Other cashflows from financing activities -0.47570M 7.83M 4.48M 4.83M 2.84M
Change to netincome 11.19M 7.06M 12.57M 6.06M 3.38M
Capital expenditures 0.48M 0.96M 0.36M 0.03M 0.23M
Change receivables - - 0.07M - -
Cash flows other operating - - 0.92M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 0.53M - -
Change in working capital 0.87M -1.19438M -1.21288M 1.87M 0.88M
Stock based compensation - 6.80M - - -
Other non cash items 11.19M 1.17M 13.81M 8.08M 3.77M
Free cash flow -12.84650M -13.17125M -12.61851M -8.75906M -5.51996M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
POAI
Predictive Oncology Inc		 -0.0099 1.66% 0.59 - - 4.02 0.86 0.72 -0.0971
ISRG
Intuitive Surgical Inc		 -3.425 0.72% 473.17 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 -2.42 2.07% 114.60 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 0.33 0.14% 233.00 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 -0.63 0.26% 239.61 47.65 17.51 3.60 2.69 4.33 19.06

Reports Covered

Stock Research & News

View All

Profile

Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.

Predictive Oncology Inc

2915 Commers Drive, Eagan, MN, United States, 55121

Key Executives

Name Title Year Born
Mr. Raymond F. Vennare CEO & Chairman 1952
Mr. Robert L. Myers M.B.A. CFO & Sec. 1955
Mr. Richard L. Gabriel B.S., B.Sc, M.B.A., MBA Sr. VP of R&D 1949
Dr. Julia Kirshner Ph.D. Chief Scientific Officer NA
Ms. Theresa Ferguson Sr. Director of Marketing NA
Ms. Pamela Bush M.B.A., Ph.D. Sr. VP of Strategic Sales & Bus. Devel. NA
Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. Sr. VP of Protein Science NA
Dr. Arlette H. Uihlein FCAP, M.D. Sr. VP of Drug Discovery Operations & Medical Director NA
Mr. Raymond F. Vennare CEO & Chairman 1953
Mr. Joshua Blacher M.B.A. Interim Chief Financial Officer 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.